Clinical Trial Detail

NCT ID NCT03759184
Title Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Obinutuzumab + rhIL-15

Age Groups: adult senior

No variant requirements are available.